AmpliPhi Biosciences (APHB) – PRNewswire
-
Armata Pharmaceuticals Announces Completion of its Phase 1b/2a 'SWARM-P.a.' Study of Inhaled AP-PA02 in Cystic Fibrosis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection
-
Armata Pharmaceuticals to Participate in the H.C. Wainwright 1st Annual Investor Conference on Bacteriophage
-
Armata Pharmaceuticals Provides Update on Pseudomonas Respiratory Programs
-
Armata Pharmaceuticals Provides Regulatory and Clinical Update Reflecting Sustained Progress Across Key Phage Therapeutic Development Programs
-
Armata Pharmaceuticals to Present at the 2021 World Antimicrobial Resistance Congress
-
Cystic Fibrosis Foundation Makes Equity Investment in Armata Pharmaceuticals
-
Armata Pharmaceuticals to Present at the Ladenburg Thalmann 2021 Healthcare Conference
-
Armata Pharmaceuticals Announces $20 Million Investment to Support Advancement of the Company's Bacteriophage Development Programs
-
Armata Pharmaceuticals Announces the Addition of Robin C. Kramer to its Board of Directors
-
Armata Pharmaceuticals Announces Participation in Upcoming Investor Conferences
Back to APHB Stock Lookup